, /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: ), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it will host an investor call on at to discuss the topline results of its Phase 3 Trial of Mino-Lok antibiotic lock solution. Citius Chairman and CEO, , will be joined by members of the management team to discuss the results of the Phase 3 Trial and the clinical need for Mino-Lok in patients with catheter-related bloodstream infections.
A question and answer period will follow management's discussion. Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. The Company's diversified pipeline includes two late-stage product candidates: Mino-Lok and LYMPHIRTM.
In , Citius announced positive topline results of Mino-Lok, its antibiotic lock solution to salvage catheters in patients with bloodstream infections. The Biologics License Application for LYMPHIR, a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma, is currently under review by the FDA with assigned as the PDUFA target action date. Citius previously announced plans to form Citius Oncology, a standalone publicly traded company with LYMPHIR as its primary asset.
LYMPHIR received orphan drug designation by the FDA for the treatment of CTCL and PTCL. In addition, Citius compl.
